Please provide your email address to receive an email when new articles are posted on . A protein known as granzyme K was recently shown to be a driver of inflammation by activating the complement ...

With Alzheimer’s disease therapies finally reaching the market and hundreds of active clinical trials for therapies and diagnostics, it seems like every week brings another potential avenue to explore ...

AJMC ®: How has treatment of complement-driven diseases changed since 2007, when the first complement inhibitor, eculizumab, was approved? SMITH: The development of eculizumab followed our ...

Clinicogenomic landscape and outcomes of metastatic colorectal cancer patients with pathogenic GNAS variants. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does ...